Deans' stroke musings: Literature Review Explores Potential Neuroprotective Effects of Resveratrol

Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Saturday, October 10, 2020

Literature Review Explores Potential Neuroprotective Effects of Resveratrol

This doesn't seem to be using the word neuroprotection as it is used in stroke for stopping the neuronal cascade of death. So don't start demanding red wine from your doctor during the first week.

Literature Review Explores Potential Neuroprotective Effects of Resveratrol

Systematic review data published in Advances in Medical Sciences provide mixed support for the benefits of resveratrol (RSV) in patients with neurodegenerative disorders. While RSV demonstrated neuroprotective effects in chemical and animal studies, few trials have assessed its use in patients at risk for Alzheimer disease.

Investigators at the Medical University of Warsaw in Poland conducted a systematic review of PubMed for experimental and clinical studies of RSV published within the last 10 years. Articles describing the pathology of Alzheimer disease and its relationship to RSV were selected. Investigators provided a summary of the literature data and commentary on RSV’s role in neurodegenerative disease prevention.

RSV is a natural phenol produced by over 70 plant species, including grapes, blueberries, cranberries, and peanuts. It has been widely studied for its antioxidant and anti-inflammatory effects. While the exact mechanism of Alzheimer disease is unclear, research suggests that oxidative stress is closely related to its development. RSV has been shown to inhibit cyclooxygenase-2 (COX-2), thus preventing oxidative damage from free radicals. RSV can also decrease the activity of tumor necrosis factor (TNF)-alpha and interleukin-1 (IL-1), leading to substantial anti-inflammatory properties. Antioxidative and anti-inflammatory effects may have implications for Alzheimer disease treatment, though further research is necessary to interpret changes in these biomarkers during treatment with RSV.

In in vitro studies, RSV was found to destabilize amyloid aggregates and inhibit the production of amyloid ß protein (Aß). Increased Aß levels correlate with cognitive decline in patients with Alzheimer disease, and Aß aggregation and accumulation are considered key risk factors for dementia. Demonstrated in 3 studies, RSV inhibits the formation of Aß-aggregates by activating the deacetylase sirtuin 1 (SIRT1) gene. RSV also promotes the tau protein demethylation and dephosphorylation. Tau proteins, like Aß, are associated with cognitive decline. By promoting effective degradation of tau proteins, RSV may prevent the formation of aggregates associated with Alzheimer disease.

Today’s Top Picks for You on Neurology Advisor

Education May Affect β-Amyloid Burden in Alzheimer Disease Anti-TNF Agents May Lower Alzheimer Disease Risk for Patients With Psoriasis, Rheumatoid Arthritis P-tau217 Shows Promise as Biomarker for Alzheimer Disease

While in vitro and in vivo studies support RSV’s protective effects, its low solubility and bioavailability limit its efficacy in humans. Efforts to increase its bioavailability include nanoencapsulation in other structure and methoxylation or hydroxylation of the RSV aromatic rings. Further study is necessary to assess the impact of these methods on RSV’s uptake. Additionally, placebo-controlled clinical trials are necessary to better elucidate the neuroprotective effect of RSV in humans. Appropriate RSV recipients may include patients with a family history of Alzheimer disease, or patients with Alzheimer disease in its early stages.

“RSV mechanisms of action indicate that it could be used in [Alzheimer disease] prevention, especially in reference to some familial forms of AD,” the investigators wrote. “The main limitations referring to such presumption include: limited [bioavailability]…and scarcity of clinical studies on RSV pertaining to large groups of humans.”